DermTech and Harvard Publish Two Clinical Studies at IID

The second clinical study “Non-invasive tape sampling reveals a type I interferon RNA signature in cutaneous lupus erythematosus that distinguishes affected from unaffected and healthy volunteer skin,” was conducted at Harvard Medical School and Brigham and Women’s Hospital. Type I interferon genes (IFN-I) are upregulated in skin lesions and blood from patients with cutaneous lupus erythematosus (CLE). This study assessed the feasibility of an adhesive tape device to collect RNA from affected and unaffected skin and its potential to detect gene expression differences between groups. The non-invasive technique demonstrated promise for the diagnosis, stratification and follow up of patients with CLE.

“Both studies demonstrate the potential of our adhesive patch skin sample collection platform to assess gene expression and mutations non-invasively in skin cancer as well as in inflammatory skin conditions,” said Dr. Burkhard Jansen, DermTech’s CMO.

About DermTech

DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit dermtech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180614006271/en/